Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of ICF004 in Healthy Chinese Participants
NCT07719218Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2026
- Primary completion
- Jul 2029
01
Overview
Phase 1, randomised, double-blind trial of ICF004 in progressive fibrosing interstitial lung disease (PF-ILD) (4 arms), sponsored by Ruijin Hospital. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ICF004
03
Conditions
progressive fibrosing interstitial lung disease (PF-ILD)
Beyond the preview
Go deeper on NCT07719218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719218.